NCT01579825已完成不适用
Evaluation of the Effect of Buffer on the Immune Response to Oral Poliovirus Vaccine in Bangladesh: a Randomized Controlled Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- Serologic response
研究概览
简要总结
Hypothesis:
The immunogenicity of oral polio vaccine (OPV) will be enhanced in Bangladeshi infants who receive bicarbonate buffer at the time of polio immunization.
详细描述
The investigators will conduct a study to evaluate the impact of administering bicarbonate buffer on the serologic responses to oral polio vaccine (OPV) in Bangladeshi infants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 4 Weeks 至 8 Weeks(Child)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •infants who are 4-8 weeks old
- •residents of study area
排除标准
- •received a blood transfusion or any other blood product (such as immune globulin)
- •likely to move out of study area within the next four months
- •currently enrolled or planning to enroll in another study
- •major congenital malformations
- •neurologic disorders
- •immunodeficiency
结局指标
主要结局
Serologic response
时间窗: 4 weeks after last dose of OPV
Serologic response rate for each polio virus serotype (1, 2, and 3) in OPV.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中(未招募)
不适用
Immunogenicity of After Primary Immunization and Booster Immunization of sIPVPolioNCT06058429Sinovac Biotech Co., Ltd233
已完成
3 期
Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)Hepatitis BNCT00393523Merck Sharp & Dohme LLC1,478
已完成
2 期
Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected SubjectsPolio ImmunityNCT01686503Eastern Virginia Medical School231
已完成
3 期
Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPVPoliomyelitisNCT03614702Institute of Medical Biology, Chinese Academy of Medical Sciences1,200
已完成
3 期
Long-term Follow-up Study of Children Previously Primed With GSK Pneumococcal Vaccine (GSK1024850A) and of Unprimed ChildrenInfections, StreptococcalNCT00950833GlaxoSmithKline466
